This article was automatically generated by Dow Jones using technology from Automated Insights.
The following companies are among those expected to report their latest financial results before the market opens.
Performance Food Group Co.'s fourth-quarter EPS is forecast at $1.27, compared with 84 cents in the prior-year period. Adjusted EPS is forecast at $1.60.
Trimble Inc.'s second-quarter EPS is forecast at 45 cents, compared with 37 cents in the prior-year period. Adjusted EPS is forecast at 80 cents.
Bio-Techne Corp.'s fourth-quarter EPS is forecast at 40 cents, compared with a loss of 11 cents in the prior-year period. Adjusted EPS is forecast at 52 cents.
Brinker International Inc.'s fourth-quarter EPS is forecast at $3.07, compared with $2.30 in the prior-year period. Adjusted EPS is forecast at $3.10.
Global-E Online Ltd.'s second-quarter EPS is forecast at 21 cents, compared with 6 cents in the prior-year period. Adjusted EPS is forecast at 22 cents.
Kontoor Brands Inc.'s second-quarter EPS is forecast at 99 cents, compared with $1.32 in the prior-year period. Adjusted EPS is forecast at $1.05.
Madison Square Garden Entertainment Corp.'s fourth-quarter EPS is forecast at a loss of 52 cents. Adjusted EPS is forecast at a loss of 44 cents.
National Vision Holdings Inc.'s second-quarter EPS is forecast at 14 cents, compared with 11 cents in the prior-year period. Adjusted EPS is forecast at 18 cents.
MeiraGTx Holdings PLC's second-quarter EPS is forecast at a loss of 35 cents, compared with a loss of 48 cents in the prior-year period. Adjusted EPS is forecast at a loss of 46 cents.
Ituran Location & Control Ltd.'s second-quarter EPS is forecast at 86 cents, compared with 67 cents in the prior-year period. Adjusted EPS is forecast at 87 cents.
Altimmune Inc.'s second-quarter EPS is forecast at a loss of 16 cents, compared with a loss of 27 cents in the prior-year period. Adjusted EPS is forecast at a loss of 0.14 cents.
Humacyte Inc.'s second-quarter EPS is forecast at a loss of 10 cents, compared with a loss of 24 cents in the prior-year period.
Acumen Pharmaceuticals Inc.'s second-quarter EPS is forecast at a loss of 34 cents, compared with a loss of 68 cents in the prior-year period. Adjusted EPS is forecast at a loss of 36 cents.
Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.